{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,21]],"date-time":"2026-06-21T07:48:49Z","timestamp":1782028129517,"version":"3.54.5"},"reference-count":26,"publisher":"American Medical Association (AMA)","issue":"11","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"abstract":"Importance<\/jats:title>Interception therapy requires individuals to undergo treatment to prevent a future medical event, but little is known about preferences of individuals at high risk for lung cancer and whether they would be interested in this type of treatment.<\/jats:p><\/jats:sec>Objective<\/jats:title>To explore preferences of individuals at high risk for lung cancer for potential interception therapies to reduce this risk.<\/jats:p><\/jats:sec>Design, Setting, and Participants<\/jats:title>This survey study used a discrete-choice experiment and included hypothetical lung cancer interception treatments with 4 attributes: reduction in lung cancer risk over 3 years, injection site reaction severity, nonfatal serious infection, and death from serious infection. Respondents were assigned to a baseline lung cancer risk of 6%, 10%, or 16% over 3 years. The discrete-choice experiment was administered online (July 13 to September 6, 2022) to US respondents eligible for lung cancer screening according to US Preventive Services Task Force guidelines. Participants included adults aged 50 to 80 years with at least a 20 pack-year smoking history. Statistical analysis was performed from September to December 2022.<\/jats:p><\/jats:sec>Main Outcomes and Measures<\/jats:title>Attribute-level preference weights were estimated, and conditional relative attribute importance, maximum acceptable risks, and minimum acceptable benefits were calculated. Characteristics of respondents who always selected no treatment were also explored.<\/jats:p><\/jats:sec>Results<\/jats:title>Of the 803 survey respondents, 495 (61.6%) were female, 138 (17.2%) were African American or Black, 55 (6.8%) were Alaska Native, American Indian, or Native American, 44 (5.5%) were Asian or Native Hawaiian or Other Pacific Islander, 104 (13.0%) were Hispanic, Latin American, or Latinx, and 462 (57.5%) were White, Middle Eastern or North African, or a race or ethnicity not listed; and mean (SD) age was 63.0 (7.5) years. Most respondents were willing to accept interception therapy and viewed reduction in lung cancer risk as the most important attribute. Respondents would accept a greater than or equal to a 12.0 percentage point increase in risk of nonfatal serious infection if lung cancer risk was reduced by at least 20.0 percentage points; and a greater than or equal to 1.2 percentage point increase in risk of fatal serious infection if lung cancer risk was reduced by at least 30.0 percentage points. Respondents would require at least a 15.4 (95% CI, 10.6-20.2) percentage point decrease in lung cancer risk to accept a 12.0 percentage point increase in risk of nonfatal serious infection; and at least a 23.1 (95% CI, 16.4-29.8) percentage point decrease in lung cancer risk to accept a 1.2 percentage point increase in risk of death from serious infection. Respondents who were unwilling to accept interception therapy in any question (129 [16.1%]) were more likely to be older and to currently smoke with no prior cessation attempt, and less likely to have been vaccinated against COVID-19 or examined for skin cancer.<\/jats:p><\/jats:sec>Conclusions and Relevance<\/jats:title>In this survey study of individuals at high risk of lung cancer, most respondents were willing to consider interception therapy. These results suggest the importance of benefit-risk assessments for future lung cancer interception treatments.<\/jats:p><\/jats:sec>","DOI":"10.1001\/jamanetworkopen.2023.42681","type":"journal-article","created":{"date-parts":[[2023,11,10]],"date-time":"2023-11-10T16:32:48Z","timestamp":1699633968000},"page":"e2342681","source":"Crossref","is-referenced-by-count":9,"title":["Patient Preferences for Lung Cancer Interception Therapy"],"prefix":"10.1001","volume":"6","author":[{"given":"Ellen M.","family":"Janssen","sequence":"first","affiliation":[{"name":"Global Epidemiology, Janssen Research and Development, Titusville, New Jersey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ian P.","family":"Smith","sequence":"additional","affiliation":[{"name":"Global Epidemiology, Janssen Research and Development, Titusville, New Jersey"},{"name":"Interventional Oncology, Johnson & Johnson External Innovation, New Brunswick, New Jersey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoying","family":"Liu","sequence":"additional","affiliation":[{"name":"RTI Health Solutions, Research Triangle Park, North Carolina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Pierce","sequence":"additional","affiliation":[{"name":"RTI Health Solutions, Research Triangle Park, North Carolina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qing","family":"Huang","sequence":"additional","affiliation":[{"name":"Interventional Oncology, Johnson & Johnson External Innovation, New Brunswick, New Jersey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iftekhar","family":"Kalsekar","sequence":"additional","affiliation":[{"name":"Interventional Oncology, Johnson & Johnson External Innovation, New Brunswick, New Jersey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anil","family":"Vachani","sequence":"additional","affiliation":[{"name":"University of Pennsylvania Perelman School of Medicine, Philadelphia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carol","family":"Mansfield","sequence":"additional","affiliation":[{"name":"RTI Health Solutions, Research Triangle Park, North Carolina"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2023,11,10]]},"reference":[{"issue":"1","key":"zoi231236r3","doi-asserted-by":"publisher","first-page":"1856","DOI":"10.1038\/s41467-019-09834-2","article-title":"Molecular subtyping reveals immune alterations associated with progression of bronchial premalignant lesions.","volume":"10","author":"Beane","year":"2019","journal-title":"Nat Commun"},{"issue":"1","key":"zoi231236r4","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1186\/s40364-021-00341-5","article-title":"Targeting interleukin-1\u00df and inflammation in lung cancer.","volume":"10","author":"Zhang","year":"2022","journal-title":"Biomark Res"},{"issue":"10105","key":"zoi231236r5","doi-asserted-by":"publisher","first-page":"1833","DOI":"10.1016\/S0140-6736(17)32247-X","article-title":"Effect of interleukin-1\u00df inhibition with canakinumab on incident lung cancer in patients with atherosclerosis: exploratory results from a randomised, double-blind, placebo-controlled trial.","volume":"390","author":"Ridker","year":"2017","journal-title":"Lancet"},{"issue":"4","key":"zoi231236r6","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1016\/j.jval.2010.11.013","article-title":"Conjoint analysis applications in health\u2013a checklist: a report of the ISPOR Good Research Practices for Conjoint Analysis Task Force.","volume":"14","author":"Bridges","year":"2011","journal-title":"Value Health"},{"issue":"4","key":"zoi231236r7","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1016\/j.jval.2016.04.004","article-title":"Statistical methods for the analysis of discrete choice experiments: a report of the ISPOR Conjoint Analysis Experimental Design Task Force.","volume":"19","author":"Hauber","year":"2016","journal-title":"Value Health"},{"issue":"1","key":"zoi231236r8","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.jval.2012.08.2223","article-title":"Constructing experimental designs for discrete-choice experiments: report of the ISPOR Conjoint Analysis Discrete-Choice Experiment Experimental Design Good Research Practices Task Force.","volume":"16","author":"Reed Johnson","year":"2013","journal-title":"Value Health"},{"key":"zoi231236r11","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1177\/002224379403100408","article-title":"Efficient experimental design with marketing research applications.","volume":"31","author":"Kuhfeld","year":"1994","journal-title":"J Mark Res"},{"issue":"2","key":"zoi231236r15","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1007\/s10549-017-4332-3","article-title":"Preferences for breast cancer risk reduction among BRCA1\/BRCA2 mutation carriers: a discrete-choice experiment.","volume":"165","author":"Liede","year":"2017","journal-title":"Breast Cancer Res Treat"},{"issue":"2","key":"zoi231236r16","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2022-002593","article-title":"Acceptable risks of treatments to prevent rheumatoid arthritis among first-degree relatives: demographic and psychological predictors of risk tolerance.","volume":"8","author":"Simons","year":"2022","journal-title":"RMD Open"},{"issue":"4","key":"zoi231236r17","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1097\/QAI.0000000000001945","article-title":"Young women\u2019s stated preferences for biomedical HIV prevention: results of a discrete choice experiment in Kenya and South Africa.","volume":"80","author":"Minnis","year":"2019","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"40","key":"zoi231236r18","doi-asserted-by":"publisher","first-page":"6022","DOI":"10.1016\/j.vaccine.2018.08.001","article-title":"Preferences for vaccines against children\u2019s diarrheal illness among mothers in Poland and Hungary.","volume":"36","author":"Poulos","year":"2018","journal-title":"Vaccine"},{"issue":"1","key":"zoi231236r19","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1023\/A:1025598106257","article-title":"The value of a statistical life: a critical review of market estimates throughout the world.","volume":"27","author":"Viscusi","year":"2003","journal-title":"J Risk Uncertain"},{"issue":"4","key":"zoi231236r20","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1198\/073500107000000287","article-title":"Health risk and portfolio choice.","volume":"26","author":"Edwards","year":"2008","journal-title":"J Bus Econ Stat"},{"issue":"3","key":"zoi231236r21","first-page":"353","article-title":"Utility-functions that depend on health-status \u2013 estimates and economic implications.","volume":"80","author":"Viscusi","year":"1990","journal-title":"Am Econ Rev"},{"issue":"4","key":"zoi231236r22","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1016\/S0167-6296(97)00025-8","article-title":"Alternative approaches to valuing intangible health losses: the evidence for multiple sclerosis.","volume":"17","author":"Sloan","year":"1998","journal-title":"J Health Econ"},{"key":"zoi231236r23","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1111\/j.1542-4774.2012.01101.x","article-title":"What good is wealth without health? The effect of health on the marginal utility of consumption.","volume":"11","author":"Finkelstein","year":"2013","journal-title":"J Eur Econ Assoc"},{"issue":"10","key":"zoi231236r24","doi-asserted-by":"publisher","first-page":"2984","DOI":"10.1007\/s00464-014-4044-2","article-title":"Incorporating patient-preference evidence into regulatory decision making.","volume":"29","author":"Ho","year":"2015","journal-title":"Surg Endosc"},{"key":"zoi231236r12","volume-title":"Marketing research methods in SAS: experimental design, choice, conjoint, and graphical techniques","author":"Kuhfeld","year":"2010"},{"key":"zoi231236r25","author":"Mansfield","year":"2019"},{"key":"zoi231236r1","unstructured":"Centers for Disease Control and Prevention. Lung cancer statistics. Accessed November 22, 2022. https:\/\/www.cdc.gov\/cancer\/lung\/statistics\/index.htm"},{"key":"zoi231236r2","unstructured":"American Cancer Society. Key statistics for lung cancer. Accessed December 23, 2020. https:\/\/www.cancer.org\/cancer\/lung-cancer\/about\/key-statistics.html"},{"key":"zoi231236r9","unstructured":"Food and Drug Administration. Patient preference information\u2014voluntary submission, review in premarket approval applications, humanitarian delivery system exemption applications, and de novo requests, and inclusion in decision summaries and delivery system labeling. Guidance for industry, Food and Drug Administration staff, and other stakeholders. Published August 2016. Accessed May 28, 2021. https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/patient-preference-information-voluntary-submission-review-premarket-approval-applications"},{"key":"zoi231236r10","unstructured":"American Association for Public Opinion Research (AAPOR). Best practices for survey research. Published March 2022. Accessed September 20, 2023. https:\/\/aapor.org\/standards-and-ethics\/best-practices\/"},{"key":"zoi231236r13","unstructured":"US Preventive Services Task Force (USPSTF). Lung cancer: screening. March 9, 2021. Accessed March 15, 2023. https:\/\/www.uspreventiveservicestaskforce.org\/uspstf\/recommendation\/lung-cancer-screening"},{"key":"zoi231236r14","unstructured":"Hensher? DA, Green? WH. The mixed logit model: the state of practice and warnings for the unwary. 2022. Accessed October 23, 2023. https:\/\/www.researchgate.net\/publication\/242076892_The_Mixed_Logit_Model_The_State_of_Practice_and_Warnings_for_the_Unwary"},{"key":"zoi231236r26","unstructured":"American Lung Association. Tobacco use in racial and ethnic populations. Published November 17, 2022. Accessed February 8, 2023. https:\/\/www.lung.org\/quit-smoking\/smoking-facts\/impact-of-tobacco-use\/tobacco-use-racial-and-ethnic"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2811642\/janssen_2023_oi_231236_1698936207.47341.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,10]],"date-time":"2023-11-10T16:32:54Z","timestamp":1699633974000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2811642"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,10]]},"references-count":26,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2023,11,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2023.42681","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,11,10]]}}}